Intratumoural administration of coxsackievirus A21 [CVA-21] for the control of malignant melanoma.
Phase of Trial: Phase I
Latest Information Update: 12 May 2017
At a glance
- Drugs CVA 21 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Viralytics
- 15 Dec 2009 Planned initiation date (Sep 2005) added as reported by Australian New Zealand Clinical Trials Registry record.
- 29 Sep 2007 New trial record.